Skip to main content
INCY
NASDAQ Industrial Applications And Services

Incyte Resolves Opzelura Medicaid Rebate Litigation, Expects $246M Q2 Benefit

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$99.73
Mkt Cap
$19.623B
52W Low
$66.74
52W High
$112.29
52W Position info
49% above low
Off High info
11% below high
Rel. Volume info
2.5× avg
Market data snapshot near publication time

INCY sits 49% above its 52-week low of $66.74 on elevated volume (2.5× avg).

Summary

Incyte announced a settlement with CMS over Medicaid rebate rules for Opzelura, resulting in a $246 million non-cash benefit in Q2 2026 and improved future profitability for the drug.


Key Events · Legal and Risk Events · INCY

  • Medicaid Rebate Litigation Resolved

    Incyte reached an agreement with the Centers for Medicare & Medicaid Services (CMS) to resolve litigation concerning the application of Medicaid rebate rules to Opzelura® (ruxolitinib) cream. CMS will not apply the line extension regulation to Opzelura as if it were a line extension of Jakafi® (ruxolitinib).

  • Significant Q2 Financial Benefit

    The company expects to record a one-time, non-cash benefit of approximately $246 million in the second quarter ending June 30, 2026. This benefit is associated with the reversal of previously established accrual balances related to potential liabilities.

  • Improved Future Profitability for Opzelura

    Incyte will no longer accrue for the potential application of the line extension regulations to Opzelura, expecting an improvement to Opzelura's gross-to-net on a go-forward basis.

  • Financial Guidance Update Planned

    The company plans to update its financial guidance to reflect the impact of this settlement during its next scheduled earnings release.


Analysis · INCY · Industrial Applications And Services

Incyte has successfully resolved its litigation with CMS regarding Medicaid rebate rules for its drug Opzelura. This agreement removes a significant regulatory uncertainty and potential liability, leading to a substantial one-time non-cash financial benefit in the second quarter. Furthermore, it is expected to improve Opzelura's ongoing profitability, which is a positive development for a key product.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, INCY was trading at $99.73 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $19.6B. The 52-week trading range was $66.74 to $112.29. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

INCY - Latest Insights

INCY
Nov 16, 2026, 4:30 PM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $117.53
Real-time Price: $116.00 info
Change: -$1.53 (-1%) info
Market Cap: $23.618B info
INCY
Oct 29, 2026, 4:03 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $116.80
Real-time Price: $116.00 info
Change: -$0.800 (-0.68%) info
Market Cap: $23.618B info
INCY
Oct 29, 2026, 11:07 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $115.20
Real-time Price: $116.00 info
Change: +$0.800 (+0.69%) info
Market Cap: $23.618B info
INCY
Oct 29, 2026, 7:00 AM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $117.76
Real-time Price: $116.00 info
Change: -$1.76 (-1%) info
Market Cap: $23.618B info
INCY
Aug 31, 2026, 4:34 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $123.22
Real-time Price: $116.00 info
Change: -$7.22 (-6%) info
Market Cap: $23.618B info